Nash, Peter
Behrens, Frank
Orbai, Ana-Maria
Rathmann, Suchitrita S
Adams, David H
Benichou, Olivier
Deodhar, Atul
Clinical trials referenced in this document:
Documents that mention this clinical trial
SAT0321 Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials
https://doi.org/10.1136/annrheumdis-2018-eular.2325
SAT0341 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis and previous inadequate response to tnf inhibitors: 52-week results from a phase 3 study
https://doi.org/10.1136/annrheumdis-2018-eular.2352
SAT0374 IXEKIZUMAB, WITH OR WITHOUT CONCOMITANT METHOTREXATE, IMPROVES THE SIGNS AND SYMPTOMS OF PSA FOR UP TO 52 WEEKS OF TREATMENT
https://doi.org/10.1136/annrheumdis-2019-eular.1240
FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.2757
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
https://doi.org/10.1136/annrheumdis-2018-215003
THU0314 Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
https://doi.org/10.1136/annrheumdis-2018-eular.2329
AB0814 SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY WITH IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS: 3-YEAR RESULTS FROM SPIRIT-P2 TRIAL
https://doi.org/10.1136/annrheumdis-2020-eular.2087
FRI0357 IMPROVED PAIN AND FATIGUE WITH IXEKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR FOLLOW-UP FROM A PHASE 3 STUDY (SPIRIT-P2)
https://doi.org/10.1136/annrheumdis-2020-eular.1362
SAT0410 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2
https://doi.org/10.1136/annrheumdis-2020-eular.3994
OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)
https://doi.org/10.1136/annrheumdis-2017-eular.1576
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
https://doi.org/10.1136/rmdopen-2019-000928
SAT0316 Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life in patients with active psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.2331
POS1033 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.567
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain (Post-results)
https://doi.org/10.1136/bmjopen-2019-032552
OP0110 IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO 1 OR 2 TUMOR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2019-eular.1479
SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.1580
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
https://doi.org/10.1136/annrheumdis-2021-222027
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
https://doi.org/10.1136/rmdopen-2018-000692
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
SAT0411 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)
https://doi.org/10.1136/annrheumdis-2020-eular.1482
FRI0426 IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAïVE PATIENTS
https://doi.org/10.1136/annrheumdis-2019-eular.1225
POS1045 Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement
https://doi.org/10.1136/annrheumdis-2021-eular.1570
AB0744 EFFICACY OF IXEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AXIAL PAIN STARTING BEFORE AGE 45: A SUBGROUP ANALYSIS OF SPIRIT-P1 AND SPIRIT-P2 PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1235
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2022-002457
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
https://doi.org/10.1136/annrheumdis-2016-209709
THU0313 Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors
https://doi.org/10.1136/annrheumdis-2018-eular.2347
AB0944 Efficacy and safety of ixekizumab when used alone or in combination with conventional disease-modifying antirheumatic drugs (CDMARDS) in tnf-experienced patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.2346
Documents that mention this clinical trial
SAT0321 Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials
https://doi.org/10.1136/annrheumdis-2018-eular.2325
SAT0341 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis and previous inadequate response to tnf inhibitors: 52-week results from a phase 3 study
https://doi.org/10.1136/annrheumdis-2018-eular.2352
SAT0374 IXEKIZUMAB, WITH OR WITHOUT CONCOMITANT METHOTREXATE, IMPROVES THE SIGNS AND SYMPTOMS OF PSA FOR UP TO 52 WEEKS OF TREATMENT
https://doi.org/10.1136/annrheumdis-2019-eular.1240
FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.2757
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
https://doi.org/10.1136/annrheumdis-2018-215003
THU0314 Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
https://doi.org/10.1136/annrheumdis-2018-eular.2329
AB0814 SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY WITH IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS: 3-YEAR RESULTS FROM SPIRIT-P2 TRIAL
https://doi.org/10.1136/annrheumdis-2020-eular.2087
FRI0357 IMPROVED PAIN AND FATIGUE WITH IXEKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR FOLLOW-UP FROM A PHASE 3 STUDY (SPIRIT-P2)
https://doi.org/10.1136/annrheumdis-2020-eular.1362
SAT0410 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2
https://doi.org/10.1136/annrheumdis-2020-eular.3994
OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)
https://doi.org/10.1136/annrheumdis-2017-eular.1576
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
https://doi.org/10.1136/rmdopen-2019-000928
SAT0316 Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life in patients with active psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.2331
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain (Post-results)
https://doi.org/10.1136/bmjopen-2019-032552
POS1033 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.567
OP0110 IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO 1 OR 2 TUMOR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2019-eular.1479
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
https://doi.org/10.1136/annrheumdis-2021-222027
SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.1580
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
https://doi.org/10.1136/rmdopen-2018-000692
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
SAT0411 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)
https://doi.org/10.1136/annrheumdis-2020-eular.1482
FRI0426 IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAïVE PATIENTS
https://doi.org/10.1136/annrheumdis-2019-eular.1225
POS1045 Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement
https://doi.org/10.1136/annrheumdis-2021-eular.1570
AB0744 EFFICACY OF IXEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AXIAL PAIN STARTING BEFORE AGE 45: A SUBGROUP ANALYSIS OF SPIRIT-P1 AND SPIRIT-P2 PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1235
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2022-002457
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
https://doi.org/10.1136/annrheumdis-2016-209709
THU0313 Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors
https://doi.org/10.1136/annrheumdis-2018-eular.2347
AB0944 Efficacy and safety of ixekizumab when used alone or in combination with conventional disease-modifying antirheumatic drugs (CDMARDS) in tnf-experienced patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.2346
Funding for this research was provided by:
Eli Lilly and Company